What is Entelos?
Entelos operates at the intersection of biotechnology and advanced computational science. By leveraging mechanism-based mathematical models, the company provides a sophisticated platform that simulates the system biology of virtual human patients. This approach allows pharmaceutical researchers to achieve higher predictive accuracy in clinical outcomes, particularly for complex conditions such as type II diabetes and cardiovascular disease. Through its expert consulting and patient stratification tools, Entelos effectively bridges the gap between theoretical research and practical trial design, ensuring that drug development teams can optimize trial parameters with unprecedented precision.
How much funding has Entelos raised?
Entelos has raised a total of $39.6M across 2 funding rounds:
Series B
$14.6M
Series C
$25M
Series B (2000): $14.6M with participation from Abingworth, Boulder Ventures, CRV, and Brentwood Associates
Series C (2012): $25M, investors not publicly disclosed
Key Investors in Entelos
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that transforms cutting-edge science into novel medicines by providing capital and expertise to top-tier management teams.
Boulder Ventures
Boulder Ventures Ltd. is a venture capital firm specializing in IT and biotech investments, with a strong track record of supporting innovative startups through their growth and IPO stages.
CRV
CRV is a long-standing venture capital firm that partners with early-stage tech startups, providing the strategic guidance and capital necessary to navigate the journey from founding to IPO.
What's next for Entelos?
With the backing of major institutional investors, Entelos is well-positioned to scale its enterprise-level operations and expand its footprint in the global drug research market. The current funding context suggests a strategic pivot toward enhancing the scalability of its predictive modeling software and deepening its consulting capabilities. As the pharmaceutical industry increasingly shifts toward data-driven patient-trial pairing, Entelos is poised to capitalize on the demand for high-fidelity simulation tools that reduce the risks associated with clinical development. Future growth will likely focus on integrating more diverse disease models and strengthening its position as a leader in the digital transformation of clinical research.
See full Entelos company page
